A non-artemisinin malaria drug matched standard treatment in African children

Almost every frontline malaria treatment in use today rests on one family of drugs: the artemisinins. That concentration is a vulnerability. As partial resistance to artemisinins spreads — first across Southeast Asia, now detected in parts of Africa — the search for effective treatments that work by a completely different mechanism has become urgent. A trial published in The Lancet Infectious Diseases on 6 November reports on one such candidate in the patients who matter most: African children [s1].

What the drug is

Ganaplacide is an antimalarial from a new chemical class that does not depend on the artemisinin mechanism [s1]. In the trial it was paired with lumefantrine — a long-acting partner drug already used in standard therapy — but reformulated as a solid dispersion formulation, a manufacturing approach designed to improve how well the drug is absorbed [s1].

The KALUMI trial, registered as NCT04546633, set out to do two things: work out how food affects drug levels, and test whether the ganaplacide combination was non-inferior to artemether-lumefantrine, the current standard, for treating uncomplicated malaria caused by Plasmodium falciparum [s1][s2].

How the trial was built

KALUMI was an open-label, multicentre, randomised, adaptive, phase 2 non-inferiority trial run at ten clinics and hospitals in Burkina Faso, Mali, Côte d'Ivoire, Gabon and the Democratic Republic of the Congo [s1]. Eligible patients had microscopically confirmed uncomplicated falciparum malaria.

The trial ran in stages. Two run-in cohorts of adolescents established the dose and examined food effects. The main part then enrolled younger children — cohort 1 aged 2 to under 12 years, cohort 2 aged 6 months to under 2 years — randomly assigned 1:1 to the ganaplacide combination or to artemether-lumefantrine [s1]. The primary endpoint was the PCR-corrected adequate clinical and parasitological response at day 29: the share of children cured of their original infection, with genetic testing used to distinguish a true cure from a fresh, unrelated new infection [s1].

Between February 2021 and July 2024, 577 patients were screened and 282 were ineligible; 51 were enrolled in the first run-in cohort, 24 in the second, and 220 in the main part, split 110 to each treatment [s1].

What it found

Food mattered for the partner drug. Across the run-in cohorts, the effect of food on ganaplacide levels was small, but lumefantrine absorption rose substantially when taken with food, with mean fed-to-fasted ratios ranging from 1.48 to 2.87 [s1]. On that basis the trial selected a regimen of ganaplacide 400 mg plus lumefantrine solid dispersion 480 mg once daily for three days, taken with a light meal [s1]. In the main part, 206 of 220 children (94%) completed the study [s1].

On the primary endpoint, the two treatments were essentially identical. PCR-corrected cure at day 29 was reached in 97 of 98 children (99%, 95% CI 94 to 100) on the ganaplacide combination and 98 of 99 (99%, 95% CI 95 to 100) on artemether-lumefantrine [s1]. The treatment difference was −0.0% (95% CI −2.9 to 2.8), and the lower bound sat well inside the prespecified 10% non-inferiority margin [s1].

Side effects differed in degree. The most common adverse events were vomiting, in 32 of 110 children (29%) on the ganaplacide combination versus 12 of 110 (11%) on artemether-lumefantrine, and hypokalaemia — low blood potassium — in 27 (25%) versus 16 (15%) [s1].

What is, and is not, established

KALUMI supports a specific conclusion: in children with uncomplicated falciparum malaria, ganaplacide plus the reformulated lumefantrine, taken once daily for three days with a light meal, cured infection as reliably as standard artemether-lumefantrine [s1]. Because ganaplacide does not rely on the artemisinin mechanism, a combination like this could matter where artemisinin resistance is emerging — the central reason for developing it [s1].

The qualifications are real. This was a phase 2 trial, and the authors report that the regimen has moved into a larger phase 3 trial, which is where non-inferiority on this scale is confirmed and rarer harms are detected [s1]. The trial was open-label, meaning patients and staff knew the assignment, though the PCR-confirmed cure endpoint limits how much that can bias the result. Vomiting and low potassium were more frequent with the new combination and will need watching in larger studies [s1]. And the day-29 window captures cure, not the longer-term questions of durability and real-world use.

This article describes research and is not medical advice.